➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Johnson and Johnson
Harvard Business School
Mallinckrodt
Merck

Last Updated: September 20, 2020

DrugPatentWatch Database Preview

Patent: 9,757,451

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,757,451
Title:Use of RANK/RANKL antagonists for treating muscular dystrophy
Abstract: The present invention relates to uses and methods comprising one or more RANK/RANKL antagonists or of a pharmaceutical composition comprising one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier for treating neuromuscular disorders, non-genetic myopathies, or genetic myopathies; maintaining and/or preserving the excitation:contraction:relaxation coupling; reducing loss of muscle strength associated with neuromuscular disorders, non-genetic myopathies or genetic myopathies; reducing the loss of muscular strength associated with skeletal or cardiac muscle disuse, diseases and aging; or regulating skeletal or cardiac muscle disuse, diseases and/or aging in a patient in need thereof. The present invention also relates to combinations and compositions comprising one or more RANK/RANKL antagonists and to methods for identifying candidate compounds.
Inventor(s): Frenette; Jerome (Quebec, CA), Penninger; Josef (Vienna, AT)
Assignee: UNIVERSITE LAVAL (Quebec, CA)
Application Number:14/356,579
Patent Claims:see list of patent claims

Details for Patent 9,757,451

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Start Trial UNIVERSITE LAVAL (Quebec, CA) 2031-11-07 RX Orphan search
Amgen XGEVA denosumab INJECTABLE; SUBCUTANEOUS 125320 002 2010-06-01   Start Trial UNIVERSITE LAVAL (Quebec, CA) 2031-11-07 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
AstraZeneca
Colorcon
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.